2440 Federal Register / Vol. 87, No. 10 / Friday, January 14, 2022 / Notices 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel; 

(SEP)—CE22–009, Rigorous Evaluation 

of Community-Level Substance Use and 

Overdose Prevention Frameworks that 

Incorporate ACEs-Related Prevention 

Strategies. 

Date: April 26–27, 2022. 

Time: 8:30 a.m., EDT. 

Place: Web Conference.. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Official, National Center for 

Injury Prevention and Control, CDC, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341, 

Telephone (404)639–6473, AWilkes@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–00718 Filed 1–13–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund the 

All-India Institute for Medical Sciences, 

New Delhi (AIIMS, New Delhi) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $2,000,000, 

with an expected total funding of 

approximately $10,000,000 over a fiveyear period, to AIIMS, New Delhi. The 

award will support research to estimate 

the incidence of influenza and other 

respiratory viruses (such as SARS-CoV– 

2) among working-age adults and other 

priority populations in India to 

strengthen the evidence base and inform 

influenza vaccine policy in India. 

DATES: The period for this award will be 

September 30, 2022, through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Amy Yang, Ph.D., National Center for 

HIV, Viral Hepatitis, STD and TB 

Prevention, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS US8–1, Atlanta, GA 30329, 

Telephone: 404–718–8835, email: corp_

erpo_8835@cdc.gov. 

SUPPLEMENTARY INFORMATION: This 

single-source award will allow the 

recipient to conduct research to estimate 

the incidence of influenza and other 

respiratory viruses (such as SARS-CoV– 

2) among working-age adults and other 

priority populations in India to 

strengthen the evidence base and inform 

influenza vaccine policy in India. 

AIIMS, New Delhi, is in a unique 

position to conduct this work, as it is 

the only institution in India with the 

required scientific and technical 

expertise to conduct multi-site cohort 

studies on influenza and other 

respiratory viruses like SARS-CoV–2 

which require robust epidemiological 

and laboratory capacity and maintains 

the high research standards required by 

CDC. AIIMS, New Delhi, is 

governmentally mandated by the AIIMS 

Act of 1956 and operates autonomously 

as an institution of national importance 

under the Ministry of Health and Family 

Welfare. AIIMS, New Delhi, is the 

leader of basic, clinical, and 

translational medical research in India. 

Summary of the Award 

Recipient: The All-India Institute for 

Medical Sciences, New Delhi (AIIMS, 

New Delhi). 

Purpose of the Award: The purpose of 

this award is to support research to 

estimate the incidence of influenza and 

other respiratory viruses, such as severe 

acute respiratory syndrome coronavirus 

2 (SARS-CoV–2), among working-aged 

adults and other priority populations in 

India to strengthen the evidence base to 

help inform influenza vaccine policy in 

India. The recipient will set up a multicenter hospital-based platform in India 

to estimate the disease and economic 

burden of influenza- and COVID–19- 

associated hospitalization of working 

age adults (18–60 years) in India. An 

additional goal is to increase awareness 

about influenza burden and prevention 

methods among clinicians and public 

health practitioners. This project aligns 

with activities conducted under the 

CDC Influenza Division’s International 

Program to build the evidence base for 

better understanding the disease and 

economic burden of influenza and to 

identify strategies for influenza 

prevention, including vaccination in 

low- and middle-income settings. 

Amount of Award: $2,000,000 in 

Federal Fiscal Year (FYY) 2022 funds, 

and an estimated $2,000,000 for each 

subsequent 12-month budget period 

over five years, subject to availability of 

funds. 

Authority: This program is authorized 

under Public Health Service Act, 

Section 307 (42 U.S.C. 242l). 

Period of Performance: September 30, 

2022 through September 29, 2027. 

Dated: January 11, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–00704 Filed 1–13–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–CE–22–011: Understanding 

Polydrug Use Risk and Protective 

Factors, Patterns, and Trajectories to 

Prevent Drug Overdose. 

Date: May 3–4, 2022. 

Time: 8:30 a.m.–5:30 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel Walters, Ph.D., Scientific Review 


lotter on DSK11XQN23PROD with NOTICES1